Knockdown of microRNA-214-3p Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Prostate Cancer.
CRISPR/Cas9
EMT
RNA sequencing
microRNA
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
received:
21
10
2021
revised:
17
11
2021
accepted:
19
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Abnormal expression of microRNA miR-214-3p (miR-214) is associated with multiple cancers. In this study, we assessed the effects of CRISPR/Cas9 mediated miR-214 depletion in prostate cancer (PCa) cells and the underlying mechanisms. Knockdown of miR-214 promoted PCa cell proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and increased resistance to anoikis, a key feature of PCa cells that undergo metastasis. The reintroduction of miR-214 in miR-214 knockdown cells reversed these effects and significantly suppressed cell proliferation, migration, and invasion. These in vitro studies are consistent with the role of miR-214 as a tumor suppressor. Moreover, miR-214 knockout increased tumor growth in PCa xenografts in nude mice supporting its anti-oncogenic role in PCa. Knockdown of miR-214 increased the expression of its target protein, Protein Tyrosine Kinase 6 (PTK6), a kinase shown to promote oncogenic signaling and tumorigenesis in PCa. In addition, miR-214 modulated EMT as exhibited by differential regulation of E-Cadherin, N-Cadherin, and Vimentin both in vitro and in vivo. RNA-seq analysis of miR-214 knockdown cells revealed altered gene expression related to PCa tumor growth pathways, including EMT and metastasis. Collectively, our findings reveal that miR-214 is a key regulator of PCa oncogenesis and is a potential novel therapeutic target for the treatment of the disease.
Identifiants
pubmed: 34884984
pii: cancers13235875
doi: 10.3390/cancers13235875
pmc: PMC8656576
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : U01CA194730
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD012767
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01MD012767
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54MD012392
Pays : United States
Organisme : NIMHD NIH HHS
ID : U24 MD015970
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD012392
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA194730
Pays : United States
Références
Onco Targets Ther. 2020 Jan 28;13:803-811
pubmed: 32095078
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
PLoS One. 2013 Oct 22;8(10):e76994
pubmed: 24167554
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
Gene. 2020 Jan 15;724:144146
pubmed: 31634561
Int J Oncol. 2019 Dec;55(6):1194-1212
pubmed: 31638194
Crit Rev Oncog. 2016;21(3-4):155-168
pubmed: 27915969
Tumour Biol. 2016 Jun;37(6):8239-48
pubmed: 26718213
Oncogene. 2013 Sep 5;32(36):4304-12
pubmed: 23027128
Gene. 2016 May 25;583(1):48-57
pubmed: 26945629
Clin Cancer Res. 2018 Jun 15;24(12):2732-2739
pubmed: 29559559
Int J Mol Med. 2018 Dec;42(6):3027-3036
pubmed: 30272290
Lab Invest. 2004 Dec;84(12):1666-76
pubmed: 15467730
Hepatology. 2014 Aug;60(2):598-609
pubmed: 24616020
Cancer Sci. 2020 Aug;111(8):2883-2894
pubmed: 32535957
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4762-9
pubmed: 24248375
Curr Opin Pharmacol. 2010 Dec;10(6):662-9
pubmed: 20832360
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562686
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3710-3716
pubmed: 32329847
World J Mens Health. 2014 Dec;32(3):167-75
pubmed: 25606566
Mol Cancer. 2015 Aug 07;14:149
pubmed: 26245467
Mol Aspects Med. 2010 Apr;31(2):205-14
pubmed: 20153362
Sci Rep. 2019 Jul 5;9(1):9776
pubmed: 31278310
Cancer Res. 2016 Aug 1;76(15):4406-17
pubmed: 27302163
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585812
PLoS One. 2012;7(9):e44206
pubmed: 22962603
Cell Mol Biol Lett. 2019 Mar 14;24:22
pubmed: 30915129
Oncotarget. 2017 Sep 21;8(50):87675-87683
pubmed: 29152111
PLoS One. 2012;7(12):e52106
pubmed: 23300597
Int J Cancer. 2006 Nov 1;119(9):2026-9
pubmed: 16671092
Chin J Cancer. 2014 Mar;33(3):140-7
pubmed: 24016392
Br J Cancer. 2016 Sep 6;115(6):741-51
pubmed: 27537384
Cell. 2012 Mar 16;148(6):1172-87
pubmed: 22424228
J Pathol. 2021 Apr;253(4):384-395
pubmed: 33314197
Oncogene. 2016 Sep 8;35(36):4752-61
pubmed: 26898757
Future Oncol. 2015;11(2):349-63
pubmed: 25591843
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24184-24195
pubmed: 31704767
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Tumour Biol. 2016 Nov;37(11):14605-14614
pubmed: 27619677
Oncogene. 2016 Apr 21;35(16):2087-97
pubmed: 26234674
Int J Biochem Cell Biol. 2011 Apr;43(4):632-41
pubmed: 21216304
Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2685-2693
pubmed: 31351129
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Am J Transl Res. 2016 Apr 15;8(4):1719-29
pubmed: 27186295
Cancer Res. 2013 Sep 1;73(17):5426-37
pubmed: 23856248
J Med Chem. 2019 Dec 26;62(24):10927-10954
pubmed: 31419130
Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115
pubmed: 28050598
Nat Rev Cancer. 2013 Oct;13(10):685-700
pubmed: 24060861
Sci Rep. 2014 Feb 03;4:3943
pubmed: 24487629
Mol Cancer. 2015 Dec 15;14:208
pubmed: 26666173
Avicenna J Med Biotechnol. 2010 Oct;2(4):161-79
pubmed: 23407304
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
Am J Cancer Res. 2016 Jan 15;6(2):127-40
pubmed: 27186391
Oncotarget. 2017 Mar 28;8(13):20881-20894
pubmed: 28152509
Tumour Biol. 2016 Jun;37(6):7473-80
pubmed: 26678890
Cancer Manag Res. 2020 Jul 28;12:6477-6491
pubmed: 32801887
Cancer Lett. 2016 Feb 28;371(2):301-13
pubmed: 26683775
Cancer Biomark. 2019;26(2):193-202
pubmed: 31403941
Am J Clin Exp Urol. 2020 Feb 25;8(1):1-8
pubmed: 32211448
J Transl Med. 2012 Nov 20;10:228
pubmed: 23164426
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Biochem Biophys Res Commun. 2017 Mar 11;484(3):623-630
pubmed: 28137590
J Invest Dermatol. 2015 Apr;135(4):960-969
pubmed: 25501033
PLoS One. 2014 May 01;9(5):e96060
pubmed: 24788754
J Exp Clin Cancer Res. 2018 Jul 18;37(1):160
pubmed: 30021600